In orthotopic animal models of breast cancer, DMTi with guadecitabine potentiated T cell recruitment, enhanced anti-tumor immunity, and exerted combinatorial activity with PD-L1-targeted immunotherapy. This evidence concerns the gene CD274 and breast cancer.